Nomura Holdings Inc. Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Nomura Holdings Inc. purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 7,649 shares of the medical equipment provider's stock, valued at approximately $551,000.

Other large investors have also bought and sold shares of the company. Principal Financial Group Inc. increased its stake in Hologic by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after purchasing an additional 1,606 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Hologic by 44.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock worth $4,595,000 after buying an additional 19,688 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of Hologic by 11.4% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 68,427 shares of the medical equipment provider's stock worth $4,933,000 after buying an additional 6,986 shares during the last quarter. Groupama Asset Managment grew its position in shares of Hologic by 63.4% in the 4th quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after buying an additional 21,037 shares during the last quarter. Finally, Olstein Capital Management L.P. grew its position in shares of Hologic by 5.9% in the 4th quarter. Olstein Capital Management L.P. now owns 90,000 shares of the medical equipment provider's stock worth $6,488,000 after buying an additional 5,000 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HOLX shares. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Evercore ISI cut their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Stephens cut their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research report on Tuesday. Finally, William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Twelve research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Hologic currently has an average rating of "Hold" and an average target price of $77.42.

Hologic Stock Up 14.5%

Shares of NASDAQ HOLX traded up $7.89 during mid-day trading on Tuesday, hitting $62.17. 19,383,033 shares of the stock traded hands, compared to its average volume of 2,213,913. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a fifty day moving average price of $58.05 and a 200-day moving average price of $66.23. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The company has a market cap of $13.85 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same period in the prior year, the firm posted $1.03 earnings per share. The company's quarterly revenue was down 1.2% on a year-over-year basis. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.